doe.unimore.itdoe.unimore.it/accreditamento10s2015/12.3. pubblicazioni... · web viewdoe.unimore.it

AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI MODENA

DIPARTIMENTO AD ATTIVITA’ INTEGRATA DIONCOLOGIA EMATOLOGIA E

PATOLOGIE DELL’ APPARATO RESPIRATORIO16 Aprile 2014

PUBBLICAZIONI SCIENTIFICHE SU RIVISTE RECENSITE DA

PUB MED

ANNI 2009-2014L’elenco è fatto per ogni componente di ruolo della Unità

Operativa, e quindi i lavori con più co-autori della stessa o altre Unità Operative del Dipartimento compaiono più volte.

1

ONCOLOGIA

PIER FRANCO CONTE

HIRSCH SCOPUS: 49

PUBBLICAZIONI 2009-2014: 77

1. Randon G, Nicoletto MO, Milite N, Muggia F, Conte P. Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor? Oncologist. 2014;19(4):429. doi: 10.1634/theoncologist.2013-0421. Epub 2014 Mar 25. PubMed PMID: 24668330; PubMed Central PMCID: PMC3983824.

2. Chan S, Campone M, Santoro A, Conte PF, Bostnavaron M, Nguyen L. A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer. Cancer Chemother Pharmacol. 2014 Mar 14. [Epub ahead of print] PubMed PMID: 24627219.

3. Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P.Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3. PubMed PMID: 24590635.

4. Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, Del Mastro L, De Placido S, Ortega C, Santini D.Targeting bone metastatic cancer: Role of the mTOR pathway. Biochim Biophys Acta. 2014 Feb 5;1845(2):248-254. doi: 10.1016/j.bbcan.2014.01.009. [Epub ahead of print] Review. PubMed PMID: 24508774.

5. Lawler M, Le Chevalier T, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Murphy MJ, Johnston PG; European Cancer Concord (ECC). A Bill of Rights for patients with cancer in Europe. Lancet Oncol. 2014 Mar;15(3):258-60. doi: 10.1016/S1470-2045(13)70552-7. Epub 2014 Feb 4. PubMed PMID: 24503530.

6. Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson

2

PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG.A Catalyst for Change: The European Cancer Patient's Bill of Rights.Oncologist. 2014;19(3):217-24. doi: 10.1634/theoncologist.2013-0452. Epub 2014 Feb 3. PubMed PMID: 24493667; PubMed Central PMCID: PMC3958470.

7. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. PubMed PMID: 24401929; PubMed Central PMCID: PMC3933248.

8. Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA). Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Ann Oncol. 2014 Apr;25(4):773-80. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18. PubMed PMID: 24351401.

9. Kaufmann M, von Minckwitz G, Bergh J, Conte PF, Darby S, Eiermann W, Howell A, Kiechle M, Mauri D, Senn HJ, Viale G, Loibl S. Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. Arch Gynecol Obstet. 2013 Dec;288(6):1203-12. doi: 10.1007/s00404-013-3069-4. Epub 2013 Nov 5. PubMed PMID: 24190694.

10. Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Aitini E, Zagonel V, Caprioni F, Villa F, Mosconi S, Faloppi L, Tonini G, Boni C, Conte P, Di Costanzo F, Cinquini M; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Dig Liver Dis. 2014 Feb;46(2):182-6. doi: 10.1016/j.dld.2013.09.020. Epub 2013 Nov 2. PubMed PMID: 24189171.

11. Baretta Z, Falci C, Piva E, Conte P. Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report. Clin Colorectal Cancer. 2013 Dec;12(4):294-6. doi: 10.1016/j.clcc.2013.09.002. PubMed PMID: 24188688.

12. Pasello G, Urso L, Conte P, Favaretto A.Effects of sulfonylureas on tumor growth: a review of the literature. Oncologist. 2013;18(10):1118-25. doi: 10.1634/theoncologist.2013-0177. Epub 2013 Sep 16. PubMed PMID: 24043597; PubMed Central PMCID: PMC3805154.

3

13. Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7. PubMed PMID: 24013581.

14. Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. PubMed PMID: 24007819.

15. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013 Nov;49(17):3648-57. doi: 10.1016/j.ejca.2013.07.144. Epub 2013 Aug 22. PubMed PMID: 23973186.

16. Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P. Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. Cancer Epidemiol Biomarkers Prev, 2013 Oct;22(10):1862-7. doi: 10.1158/1055-9965.EPI-13-0595. Epub 2013 Aug 14. PubMed PMID: 23945199.

17. Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6. Review. PubMed PMID: 23842749.

18. Piccinno MS, Veronesi E, Loschi P, Pignatti M, Murgia A, Grisendi G, Castelli I, Bernabei D, Candini O, Conte P, Paolucci P, Horwitz EM, De Santis G, Iughetti L, Dominici M. Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. Apoptosis. 2013 Oct;18(10):1274-89. doi: 10.1007/s10495-013-0878-7. PubMed PMID: 23828239; PubMed Central PMCID: PMC3775159.

19. Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, Espie M, Majois F, Gil MG, Vaissiere N, Villanova G. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res. 2013 Jun;33(6):2657-64. PubMed PMID: 23749924.

20. Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X.

4

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun;139(2):411-9. doi: 10.1007/s10549-013-2552-8. Epub 2013 May 7. PubMed PMID: 23649189; PubMed Central PMCID: PMC3669514.

21. Hortobágyi G, Conte P. Interpreting cancer biology: refining our therapeutic algorithm in breast cancer. Oncologist. 2013;18(4):e8-10. doi: 10.1634/theoncologist.2013-0117. PubMed PMID: 23633451; PubMed Central PMCID: PMC3639541.

22. Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, Veronesi E, Loschi P, Masini C, Conte P, Paolucci P, Horwiz EM, Dominici M. Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. Biomed Res Int. 2013;2013:901821. doi: 10.1155/2013/901821. Epub 2013 Mar 31. PubMed PMID: 23607099; PubMed Central PMCID: PMC3626323.

23. Arpino G, Generali D, Sapino A, Del Matro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L. Gene expression profiling in breast cancer: a clinical perspective. Breast. 2013 Apr;22(2):109-20. doi: 10.1016/j.breast.2013.01.016. Epub 2013 Feb 23. Review. PubMed PMID: 23462680.

24. Bertolini F, Zunarelli E, Baraldi C, Valentini A, Del Giovane C, Depenni R, Falasca A, Giacobazzi P, Malagoli M, Meletti S, Fontana A, Conte P; Gruppo Neuro Oncologico Modena (GNO-MO). Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series. Tumori. 2012 Nov;98(6):756-61. doi: 10.1700/1217.13500. PubMed PMID: 23389363.

25. Alicandri-Ciufelli M, Bonali M, Piccinini A, Marra L, Ghidini A, Cunsolo EM, Maiorana A, Presutti L, Conte PF. Surgical margins in head and neck squamous cell carcinoma: what is 'close'? Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2603-9. doi: 10.1007/s00405-012-2317-8. Epub 2012 Dec 28. PubMed PMID: 23271033.

26. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol. 2013 Dec;64(6):994-1002. doi: 10.1016/j.eururo.2012.11.032. Epub 2012 Nov 21. PubMed PMID: 23219086.

27. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.

5

Ann Oncol. 2013 Jan;24(1):101-8. doi: 10.1093/annonc/mds248. Epub 2012 Sep 20. PubMed PMID: 23002281.

28. D'souza N1, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M.MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential.Adv Biochem Eng Biotechnol. 2013;130:209-66. doi: 10.1007/10_2012_150. PMID: 22990585

29. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. PubMed PMID: 22995653.

30. Cortesi L, Marcheselli L, Guarneri V, Cirilli C, Braghiroli B, Toss A, Sant M, Ficarra G, Conte PF, Federico M. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. Int J Cancer. 2013 Jan 15;132(2):E58-65. doi: 10.1002/ijc.27795. Epub 2012 Sep 21. PubMed PMID: 22915138.

31. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRMInvestigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15. PubMed PMID: 22894553.

32. Conte P, Guarneri V. The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer. Clin Breast Cancer. 2012 Jun;12(3):157-66. doi: 10.1016/j.clbc.2012.03.005. Review. PubMed PMID: 22607765.

33. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012 Jun 1;30(16):1989-95. doi: 10.1200/JCO.2011.39.0823. Epub 2012 Apr 9. PubMed PMID: 22493419.

34. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J.

6

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5. PubMed PMID: 22393084.

35. Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. J Clin Pathol. 2012 Jun;65(6):503-6. doi: 10.1136/jclinpath-2011-200643. Epub 2012 Mar 3. PubMed PMID: 22389512.

36. Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 2012 Sep;110(5):692-8. doi: 10.1111/j.1464-410X.2012.10946.x. Epub 2012 Feb 24. PubMed PMID: 22364110.

37. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we?Ann Oncol. 2012 Jun;23(6):1378-86. doi: 10.1093/annonc/mdr593. Epub 2012 Feb 8. Review. PubMed PMID: 22317766.

38. Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20. PubMed PMID: 22265698.

39. Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother. 2012 Feb;13(3):395-406. doi: 10.1517/14656566.2012.651127. Epub 2012 Jan 21. Review. PubMed PMID: 22263900.

40. Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012 Feb 20;30(6):e76-8. doi: 10.1200/JCO.2011.38.7886. Epub 2011 Dec 27. PubMed PMID: 22203769.

7

41. Bertolini F, Rossi G, Fiocchi F, Giacometti M, Fontana A, Gibertini MC, Roncucci L, Luppi G, Torricelli P, Rossi A, Conte PF.Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor. Tumori. 2011 Sep-Oct;97(5):27e-30e. doi: 10.1700/989.10734.PubMed PMID: 22158506.

42. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr. 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037. PubMed PMID: 22043063.

43. Guarneri V, Barbieri E, Conte P. Biomarkers predicting clinical benefit: fact or fiction? J Natl Cancer Inst Monogr. 2011;2011(43):63-6. doi: 10.1093/jncimonographs/lgr021. PubMed PMID: 22043043.

44. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, Loschi P, Pignatti M, Di Benedetto F, Ballarin R, Di Gregorio C, Guarneri V, Piccinini L, Horwitz EM, Paolucci P, Conte P, Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res. 2011;1(6):787-805. Epub 2011 May PubMed PMID: 22016827; PubMed Central PMCID: PMC3195936.

45. Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast. 2012 Feb;21(1):20-6. doi: 10.1016/j.breast.2011.09.006. Epub 2011 Oct 8. Review. PubMed PMID: 21983489.

46. Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab treatment for advanced breast cancer. Oncologist. 2011;16(12):1684-97. doi: 10.1634/theoncologist.2011-0113. Epub 2011 Oct 5. Review. PubMed PMID: 21976315; PubMed Central PMCID: PMC3248767.

47. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group.

8

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29. PubMed PMID: 21803569.

48. Adamo V, Ricciardi GR, De Placido S, Colucci G, Conte P, Giuffrida D, Gebbia N, Masci G, Cognetti F, Dondi D, Venturini M.Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer. 2012 Mar;48(5):642-7. doi: 10.1016/j.ejca.2011.06.028. Epub 2011 Jul 13. PubMed PMID: 21757335.

49. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. PubMed PMID: 21612468; PubMed Central PMCID: PMC3471149.

50. Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Cancer. 2012 Jan 15;118(2):461-8. doi: 10.1002/cncr.26213. Epub 2011 May 19. PubMed PMID: 21598243.

51. Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S, Fontana A, Pettorelli E, Luppi G, Conte PF. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer. 2011 Mar 29;104(7):1079-84. doi: 10.1038/bjc.2011.43. Epub 2011 Mar 8. PubMed PMID: 21386839; PubMed Central PMCID: PMC3068493.

52. Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. Ann Surg Oncol. 2011 Aug;18(8):2150-7. doi: 10.1245/s10434-011-1590-x. Epub 2011 Feb 8. PubMed PMID: 21301969.

53. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Timing for starting second-line therapy in recurrent ovarian cancer. Expert Rev Anticancer Ther. 2011 Jan;11(1):49-55. doi: 10.1586/era.10.204. Review. PubMed PMID: 21166510.

9

54. Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S62-6. doi: 10.1016/S0305-7372(10)70022-0. Review. PubMed PMID: 21129613.

55. Roché H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 2011 Feb;125(3):755-65. doi: 10.1007/s10549-010-1251-y. Epub 2010 Dec 3. PubMed PMID: 21128114.

56. Bengala C, Bettelli S, Bertolini F, Sartori G, Fontana A, Malavasi N, Depenni R, Zironi S, Del Giovane C, Luppi G, Conte PF. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Br J Cancer. 2010 Sep 28;103(7):1019-24. doi: 10.1038/sj.bjc.6605853. Epub 2010 Sep 14. PubMed PMID: 20842128; PubMed Central PMCID: PMC2965865.

57. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256-65. doi: 10.1002/cncr.25219. PubMed PMID: 20549832.

58. Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A, D'Amico R, Conte P. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. Int J Biol Markers. 2010 Apr-Jun;25(2):104-11. PubMed PMID: 20544688.

59. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63. doi: 10.1200/JCO.2009.24.4244. Epub 2010 Jun 7. PubMed PMID: 20530276; PubMed Central PMCID: PMC2903325.

60. Ponti G, Luppi G, Giacobbi F, Corradini G, Temperani P, Losi L, Ferrara L, Pagano M, Seidenari S, Tagliafico E, Torelli G, Conte P. Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. Cancer Genet Cytogenet. 2010 Jul 1;200(1):1-7. doi: 10.1016/j.cancergencyto.2009.10.006. PubMed PMID: 20513527.

10

61. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010 May 1;70(9):3718-29. doi: 10.1158/0008-5472.CAN-09-1865. Epub 2010 Apr 13. PubMed PMID: 20388793.

62. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2. PubMed PMID: 20361252.

63. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010 Mar 1;28(7):1138-44. doi: 10.1200/JCO.2009.24.2024. Epub 2010 Feb 1. PubMed PMID: 20124182.

64. Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010 May;117(2):152-8. doi: 10.1016/j.ygyno.2009.11.033. Epub 2010 Jan 6. Review. PubMed PMID: 20056266.

65. Ponti G, Luppi G, Martorana D, Rossi G, Losi L, Bertolini F, Sartori G, Pellacani G, Seidenari S, Boni E, Neri TM, Silini E, Tamburini E, Maiorana A, Conte PF. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep. 2010 Feb;23(2):437-44. PubMed PMID: 20043105.

66. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G, Conte P. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010 Jan 5;102(1):68-72. doi: 10.1038/sj.bjc.6605458. Epub 2009 Nov 24. PubMed PMID: 19935794; PubMed Central PMCID: PMC2813746.

67. Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol. 2010 Mar;21(3):474-80. doi: 10.1093/annonc/mdp373. Epub 2009 Oct 8. PubMed PMID: 19815649.

11

68. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009 Oct 1;27(28):4642-8. doi: 10.1200/JCO.2009.21.9691. Epub 2009 Aug 24. PubMed PMID: 19704064.

69. Malavasi N, Ponti G, Depenni R, Bertolini F, Zironi S, Luppi G, Conte PF. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol. 2009 Aug 6;2:35. doi: 10.1186/1756-8722-2-35. PubMed PMID: 19660136; PubMed Central PMCID: PMC2731036.

70. Frassoldati A, Guarneri V, Conte P. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1456-8. Epub 2009 Aug 5. PubMed PMID: 19617703.

71. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009 Jul;14(7):645-56. doi: 10.1634/theoncologist.2009-0078. Epub 2009 Jul 16. Review. PubMed PMID: 19608638.

72. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N, Villanova G. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer. 2009 Jul 21;101(2):232-7. doi: 10.1038/sj.bjc.6605156. Epub 2009 Jul 7. PubMed PMID: 19584872; PubMed Central PMCID: PMC2720198.

73. Gadducci A, Katsaros D, Zola P, Scambia G, Ballardini M, Pasquini E, Fertonani C, Maggi L, Pecorelli S, Conte PF; Members of the After-6 Italian Cooperative Group. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). Int J Gynecol Cancer. 2009 May;19(4):615-9. doi: 10.1111/IGC.0b013e3181a4476b. PubMed PMID: 19509559.

74. Dominici M, Paolucci P, Conte P, Horwitz EM. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation. 2009 May 15;87(9 Suppl):S36-42. doi: 10.1097/TP.0b013e3181a283ee. PubMed PMID: 19424002.

12

75. Dominici M, Rasini V, Bussolari R, Chen X, Hofmann TJ, Spano C, Bernabei D, Veronesi E, Bertoni F, Paolucci P, Conte P, Horwitz EM. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood. 2009 Sep 10;114(11):2333-43. doi: 10.1182/blood-2008-10-183459. Epub 2009 May 11. PubMed PMID: 19433859; PubMed Central PMCID: PMC2745851.

76. Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D'Amico R, Giovannelli S, Maiorana A, Jovic G, Conte P. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol. 2009 Jul;20(7):1193-8. doi: 10.1093/annonc/mdn761. Epub 2009 Feb 16. PubMed PMID: 19221152.

77. Gennari A, De Tursi M, Carella C, Ricevuto E, Orlandini C, Frassoldati A, Conte P, Bruzzi P, Iacobelli S. Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Res Treat. 2009 May;115(1):131-6. doi: 10.1007/s10549-008-0048-8. Epub 2008 Sep 13. PubMed PMID: 18791821.

13

ONCOLOGIA

FAUSTO BARBIERI

HIRSCH SCOPUS: 12


1. Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. PubMed PMID: 23109689.

2. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer. 2012 Oct;78(1):92-9. doi: 10.1016/j.lungcan.2012.07.009. Epub 2012 Aug 11. PubMed PMID: 22889494.

3. Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer. 2011 Jul;73(1):78-88. doi: 10.1016/j.lungcan.2010.10.020. Epub 2010 Dec 8. PubMed PMID: 21144614.

4. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, Uliano M. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma. Lung Cancer. 2010 Aug;69(2):187-93. doi: 10.1016/j.lungcan.2009.10.015. Epub 2009 Nov 25. PubMed PMID: 19942313.

5. Sartori G, Cavazza A, Sgambato A, Marchioni A, Barbieri F, Longo L, Bavieri M, Murer B, Meschiari E, Tamberi S, Cadioli A, Luppi F, Migaldi M, Rossi G.

14

EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol. 2009 Apr;131(4):478-89. doi: 10.1309/AJCPH0TRMPXVZW2F. PubMed PMID: 19289583.

15

ONCOLOGIA

PAOLA BRESCIANI

HIRSCH SCOPUS: 5


1. Iacobucci I, Lonetti A, Venturi C, Ferrari A, Papayannidis C, Ottaviani E, Abbenante MC, Paolini S, Bresciani P, Potenza L, Parisi S, Cattina F, Soverini S, Russo D, Luppi M, Martinelli G. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res. 2014 Feb 18. pii: S0145-2126(14)00053-8. doi: 10.1016/j.leukres.2014.02.005. [Epub ahead of print] PubMed PMID: 24630366.

2. Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, Martinelli G. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014 Apr 1;120(7):1002-9. doi: 10.1002/cncr.28522. Epub 2013 Dec 30. PubMed PMID: 24382642.

3. Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabrielli A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F, Poloni A, Olivieri J, Leoni P, Bacigalupo A.Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood. 2013 Dec 12;122(25):4111-8. doi: 10.1182/blood-2013-05-494278. Epub 2013 Oct 23. PubMed PMID: 24152907.

4. Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013 Aug 29;122(9):1634-48. doi: 10.1182/blood-2013-03-487728. Epub 2013 Jun 21. PubMed PMID: 23794064.

5. D'Andrea MM, Venturelli C, Giani T, Arena F, Conte V, Bresciani P, Rumpianesi F, Pantosti A, Narni F, Rossolini GM. Persistent carriage and infection by multidrug-resistant Escherichia coli ST405 producing NDM-1 carbapenemase: report on the first Italian cases.

16

J Clin Microbiol. 2011 Jul;49(7):2755-8. doi: 10.1128/JCM.00016-11. Epub 2011 Apr 27. PubMed PMID: 21525229; PubMed Central PMCID: PMC3147842.

17

ONCOLOGIA

LAURA CORTESI

HIRSCH SCOPUS: 16


1. Baviera M, Santalucia P, Cortesi L, Marzona I, Tettamanti M, Avanzini F, Nobili A, Riva E, Caso V, Fortino I, Bortolotti A, Merlino L, Roncaglioni MC. Sex differences in cardiovascular outcomes, pharmacological treatments and indicators of care in patients with newly diagnosed diabetes: Analyses on administrative database. Eur J Intern Med. 2014 Mar;25(3):270-5. doi: 10.1016/j.ejim.2014.01.022. Epub 2014 Feb 18. PubMed PMID: 24556165.

2. Pashaj E, Cortesi L, Proietto M, Bonacorsi G, Liardo E, Federico M. A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate. Future Oncol. 2013 Oct;9(10):1437-42. doi: 10.2217/fon.13.158. PubMed PMID: 24106895.

3. Cortesi L, De Matteis E, Cirilli C, Filieri E, Pecchi A, Battista R, Canossi B, Torricelli P, Federico M. MRI before initial surgery outside of clinical trials: the real world! Eur J Radiol. 2012 Sep;81 Suppl 1:S21-3. doi: 10.1016/S0720-048X(12)70009-8. PubMed PMID: 23083589.

4. Cortesi L, Pecchi A, De Matteis E, Filieri E, Battista R, Canossi B, Torricelli P, Federico M. MRI in high risk women: benefits and problems. Eur J Radiol. 2012 Sep;81 Suppl 1:S19-20. doi: 10.1016/S0720-048X(12)70008-6. PubMed PMID: 23083587.

5. Toss A, De Matteis E, Rossi E, Casa LD, Iannone A, Federico M, Cortesi L. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?Int J Mol Sci. 2013 Apr 15;14(4):8271-90. doi: 10.3390/ijms14048271. PubMed PMID: 23591842; PubMed Central PMCID: PMC3645742.

6. Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women. Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498. PubMed PMID: 23389361.

7. Razzaboni E, Toss A, Cortesi L, Marchi I, Sebastiani F, De Matteis E, Federico M. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). Breast J. 2013 Jan-Feb;19(1):10-21. doi: 10.1111/tbj.12045. Epub 2012 Dec 17. PubMed PMID: 23252601.

18

8. Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Casadio C, Jemos C, Pizzamiglio M, Cortesi L, Radice D, Bonanni B. Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo. BMC Cancer. 2012 Dec 5;12:575. doi: 10.1186/1471-2407-12-575. PubMed PMID: 23216985; PubMed Central PMCID: PMC3522001.

9. Cortesi L, Marcheselli L, Guarneri V, Cirilli C, Braghiroli B, Toss A, Sant M, Ficarra G, Conte PF, Federico M. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. Int J Cancer. 2013 Jan 15;132(2):E58-65. doi: 10.1002/ijc.27795. Epub 2012 Sep 21. PubMed PMID: 22915138.

10. Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012 Jul;134(1):411-8. doi: 10.1007/s10549-012-2062-0. Epub 2012 Apr PubMed PMID: 22527108.

11. Cortesi L, De Nicolo A, Medici V, Marino M, Turchetti D, Pradella LM, Rossi G, Parisini E, Federico M. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat. Breast Cancer Res Treat. 2012 Jul;134(1):435-41. doi: 10.1007/s10549-012-2052-2. Epub 2012 Apr 22. PubMed PMID: 22527099.

12. Cortesi L, Proietto M, Cirilli C, Tazzioli G, Andreotti A, Federico M. Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. J Surg Oncol. 2012 Sep 15;106(4):399-405. doi: 10.1002/jso.23111. Epub 2012 Apr 4. PubMed PMID: 22488263.

13. Franchi C, Tettamanti M, Marengoni A, Bonometti F, Pasina L, Cortesi L, Fortino I, Bortolotti A, Merlino L, Lucca U, Riva E, Nobili A. Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur Neuropsychopharmacol. 2012 Aug;22(8):569-77. doi: 10.1016/j.euroneuro.2011.12.009. Epub 2012 Jan 31. PubMed PMID: 22297160.

14. Cortesi L, Rossi E, Della Casa L, Barchetti A, Nicoli A, Piana S, Abrate M, La Sala GB, Federico M, Iannone A. Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis. 2011 Aug;32(15):1992-2003. doi: 10.1002/elps.201000654. Epub 2011 Jul 4. PubMed PMID: 21728179.

19

15. Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Riva E, Cortesi L, Bortolotti A, Fortino I, Merlino L, Fontana G, Roncaglioni MC. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract. 2011 Jul;93(1):123-30. doi: 10.1016/j.diabres.2011.05.004. Epub 2011 May 31. PubMed PMID: 21621869.

16. Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, Vergnaghi D, Federico M, Cortesi L, Corcione S, Morassut S, Di Maggio C, Cilotti A, Martincich L, Calabrese M, Zuiani C, Preda L, Bonanni B, Carbonaro LA, Contegiacomo A, Panizza P, Di Cesare E, Savarese A, Crecco M, Turchetti D, Tonutti M, Belli P, Maschio AD; High Breast Cancer Risk Italian 1 (HIBCRIT-1) Study. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol. 2011 Feb;46(2):94-105. doi: 10.1097/RLI.0b013e3181f3fcdf. PubMed PMID: 21139507.

17. Crocetti E, Buzzoni C, Falcini F, Cortesi L, De Lisi V, Ferretti S, Tumino R, Russo A, Paci E. Disentangling the roles of mammographic screening and HRT in recent breast cancer incidence trends in italy by analyses based on calendar time and time since screening activation. Breast J. 2010 Jul-Aug;16(4):350-5. doi: 10.1111/j.1524-4741.2010.00928.x. Epub 2010 Apr 23. PubMed PMID: 20443789.

18. Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, Pasini G, Turchetti D, Federico M. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer. 2010 Mar 10;10:90. doi: 10.1186/1471-2407-10-90. PubMed PMID: 20219108; PubMed Central PMCID: PMC2847959.

19. Cortesi L, De Matteis E, Rashid I, Cirilli C, Proietto M, Rivasi F, Federico M. Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer. 2009 Nov;19(8):1358-63. doi: 10.1111/IGC.0b013e3181b9f5d5. PubMed PMID: 20009890.

20. Cortesi L, Barchetti A, De Matteis E, Rossi E, Della Casa L, Marcheselli L, Tazzioli G, Lazzaretti MG, Ficarra G, Federico M, Iannone A. Identification of protein clusters predictive of response to chemotherapy in breast cancer patients. J Proteome Res. 2009 Nov;8(11):4916-33. doi: 10.1021/pr900239h. PubMed PMID: 19739612.

21. Pecorari L, Marin O, Silvestri C, Candini O, Rossi E, Guerzoni C, Cattelani S, Mariani SA, Corradini F, Ferrari-Amorotti G, Cortesi L, Bussolari R, Raschellà G, Federico MR, Calabretta B. Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Mol Cancer. 2009 Aug 3;8:58. doi: 10.1186/1476-4598-8-58. PubMed PMID: 19646290; PubMed Central PMCID: PMC2727493.

20

22. Marino M, Rabacchi C, Simone ML, Medici V, Cortesi L, Calandra S. A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region. Clin Chim Acta. 2009 May;403(1-2):249-53. doi: 10.1016/j.cca.2009.02.020. Epub 2009 Mar 25. PubMed PMID: 19393826.

21

ONCOLOGIA

MASSIMO DOMINICI

HIRSCH SCOPUS: 22


1. Zhao W, Phinney DG, Bonnet D, Dominici M, Krampera M. Mesenchymal stem cell biodistribution, migration, and homing in vivo. Stem Cells Int. 2014;2014:292109. doi: 10.1155/2014/292109. Epub 2014 Mar 11. PubMed PMID: 24738002.

2. Marino R, Otsuru S, Hofmann TJ, Olson TS, Rasini V, Veronesi E, Boyd K, Gaber MW, Martinez C, Paolucci P, Dominici M, Horwitz EM. Delayed marrow infusion in mice enhances hematopoietic and osteopoietic engraftment by facilitating transient expansion of the osteoblastic niche. Biol Blood Marrow Transplant. 2013 Nov;19(11):1566-73. doi: 10.1016/j.bbmt.2013.07.025. Epub 2013 Aug 2. PubMed PMID: 23916672.

3. Veronesi E, Murgia A, Caselli A, Grisendi G, Piccinno MS, Rasini V, Giordano R, Montemurro T, Bourin P, Sensebé L, Rojewski MT, Schrezenmeier H, Layrolle P, Ginebra MP, Panaitescu CB, Gómez-Barrena E, Catani F, Paolucci P, Burns JS, Dominici M. Transportation conditions for prompt use of ex vivo expanded and freshly harvested clinical-grade bone marrow mesenchymal stromal/stem cells for bone regeneration. Tissue Eng Part C Methods. 2014 Mar;20(3):239-51. doi: 10.1089/ten.TEC.2013.0250. Epub 2013 Aug 20. PubMed PMID: 23845029; PubMed Central PMCID: PMC3936497.

4. Piccinno MS, Veronesi E, Loschi P, Pignatti M, Murgia A, Grisendi G, Castelli I, Bernabei D, Candini O, Conte P, Paolucci P, Horwitz EM, De Santis G, Iughetti L, Dominici M. Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. Apoptosis. 2013 Oct;18(10):1274-89. doi: 10.1007/s10495-013-0878-7. PubMed PMID: 23828239; PubMed Central PMCID: PMC3775159.

5. Caselli A, Olson TS, Otsuru S, Chen X, Hofmann TJ, Nah HD, Grisendi G, Paolucci P, Dominici M, Horwitz EM. IGF-1-mediated osteoblastic niche expansion enhances long-term hematopoietic stem cell engraftment after murine bone marrow transplantation. Stem Cells. 2013 Oct;31(10):2193-204. doi: 10.1002/stem.1463. PubMed PMID: 23818291.

6. Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation.

22

Eur J Immunol. 2013 Oct;43(10):2741-9. doi: 10.1002/eji.201343335. Epub 2013 Jul 23. PubMed PMID: 23817958.

7. Olson TS, Caselli A, Otsuru S, Hofmann TJ, Williams R, Paolucci P, Dominici M, Horwitz EM. Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. Blood. 2013 Jun 27;121(26):5238-49. doi: 10.1182/blood-2012-10-463414. Epub 2013 May 10. PubMed PMID: 23667055; PubMed Central PMCID: PMC3695366.

8. Rossignoli F, Caselli A, Grisendi G, Piccinno S, Burns JS, Murgia A, Veronesi E, Loschi P, Masini C, Conte P, Paolucci P, Horwiz EM, Dominici M. Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. Biomed Res Int. 2013;2013:901821. doi: 10.1155/2013/901821. Epub 2013 Mar 31. PubMed PMID: 23607099; PubMed Central PMCID: PMC3626323.

9. Hofmann TJ, Otsuru S, Marino R, Rasini V, Veronesi E, Murgia A, Lahti J, Boyd K, Dominici M, Horwitz EM. Transplanted murine long-term repopulating hematopoietic cells can differentiate to osteoblasts in the marrow stem cell niche. Mol Ther. 2013 Jun;21(6):1224-31. doi: 10.1038/mt.2013.36. Epub 2013 Apr PubMed PMID: 23587920; PubMed Central PMCID: PMC3677312.

10. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT).Cytotherapy. 2013 Jun;15(6):641-8. doi: 10.1016/j.jcyt.2013.02.006. Epub 2013 Apr 6. PubMed PMID: 23570660; PubMed Central PMCID: PMC3979435.

11. Kramer J, Dazzi F, Dominici M, Schlenke P, Wagner W. Clinical perspectives of mesenchymal stem cells. Stem Cells Int. 2012;2012:684827. doi: 10.1155/2012/684827. Epub 2012 Dec 24. PubMed PMID: 23319960; PubMed Central PMCID: PMC3540921.

12. Rasini V, Dominici M, Kluba T, Siegel G, Lusenti G, Northoff H, Horwitz EM, Schäfer R. Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy. 2013 Mar;15(3):292-306. doi: 10.1016/j.jcyt.2012.11.009. Epub 2013 Jan 9. PubMed PMID: 23312449.

13. Ferrari-Amorotti G, Fragliasso V, Esteki R, Prudente Z, Soliera AR, Cattelani S, Manzotti G, Grisendi G, Dominici M, Pieraccioli M, Raschellà G, Chiodoni C, Colombo MP, Calabretta B. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res. 2013 Jan 1;73(1):235-45. doi: 10.1158/0008-5472.CAN-12-1739. Epub 2012 Oct 10. PubMed PMID: 23054398; PubMed Central PMCID: PMC3537890.

23

14. D'souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M. MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. Adv Biochem Eng Biotechnol. 2013;130:209-66. doi: 10.1007/10_2012_150. PubMed PMID: 22990585.

15. Burns JS, Safwat A, Grisendi G, Kassem M, Dominici M. Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy. Cancer Lett. 2012 Dec 1;325(1):1-10. doi: 10.1016/j.canlet.2012.05.027. Epub 2012 May 29. Review. PubMed PMID: 22659735.

16. Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips CL, Hofmann TJ, Veronesi E, Dominici M, Iwamoto M, Horwitz EM. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood. 2012 Aug 30;120(9):1933-41. doi: 10.1182/blood-2011-12-400085. Epub 2012 Jul 24. PubMed PMID: 22829629; PubMed Central PMCID: PMC3433095.

17. Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F, Silvestris F. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol. 2012 Jun;157(5):586-98. doi: 10.1111/j.1365-2141.2012.09082.x. Epub 2012 Mar 16. PubMed PMID: 22420897.


19. Virzì GM, Torregrossa R, Cruz DN, Chionh CY, de Cal M, Soni SS, Dominici M, Vescovo G, Rosner MH, Ronco C. Cardiorenal Syndrome Type 1 May Be Immunologically Mediated: A Pilot Evaluation of Monocyte Apoptosis. Cardiorenal Med. 2012 eb;2(1):33-42. Epub 2012 Jan 20. PubMed PMID: 22493601; PubMed Central PMCID: PMC3318942.

20. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, Loschi P, Pignatti M, Di Benedetto F, Ballarin R, Di Gregorio C, Guarneri V, Piccinini L, Horwitz EM, Paolucci P, Conte P, Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.

24

Am J Cancer Res. 2011;1(6):787-805. Epub 2011 May 28. PubMed PMID: 22016827; PubMed Central PMCID: PMC3195936.

21. Otsuru S, Rasini V, Bussolari R, Hofmann TJ, Dominici M, Horwitz EM. Cytokine-induced osteopoietic differentiation of transplanted marrow cells. Blood. 2011 Aug 25;118(8):2358-61. doi: 10.1182/blood-2011-01-331397. Epub 2011 Jun 29. PubMed PMID: 21715305; PubMed Central PMCID: PMC3162360.

22. Barti-Juhasz H, Mihalik R, Nagy K, Grisendi G, Dominici M, Petak I. Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro. Haematologica. 2011 Mar;96(3):e21-2. doi: 10.3324/haematol.2010.036822. PubMed PMID: 21357712; PubMed Central PMCID: PMC3046290.

23. Ciavarella S, Dominici M, Dammacco F, Silvestris F. Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev. 2011 Jan;20(1):1-10. doi: 10.1089/scd.2010.0223. Epub 2010 Sep 14. Review. PubMed PMID: 20670160.

24. Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood. 2010 Nov 11;116(19):3770-9. doi: 10.1182/blood-2010-02-270777. Epub 2010 Jul 19. PubMed PMID: 20644118.

25. Dominici M, Horwitz EM. Getting beneath the skin to understand MSC complexity. Cytotherapy. 2010 Jul;12(4):438-9. doi: 10.3109/14653249.2010.499712. PubMed PMID: 20608761.

26. Otsuru S, Hofmann TJ, Rasini V, Veronesi E, Dominici M, Horwitz EM. Osteopoietic engraftment after bone marrow transplantation: effect of inbred strain of mice. Exp Hematol. 2010 Sep;38(9):836-44. doi: 10.1016/j.exphem.2010.04.015. Epub 2010 May 4. PubMed PMID: 20447443; PubMed Central PMCID: PMC3392015.

27. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010 May 1;70(9):3718-29. doi: 10.1158/0008-5472.CAN-09-1865. Epub 2010 Apr 13. PubMed PMID: 20388793.

28. Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, Luminari S, Maur M, Frassoldati A, Palazzi G, Otsuru S, Bambi F, Paolucci P, Pierfranco C, Horwitz E, Dominici M. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy. 2010 Jul;12(4):466-77. doi: 10.3109/14653241003649510. PubMed PMID: 20353309.

25

29. Parolini O, Alviano F, Bergwerf I, Boraschi D, De Bari C, De Waele P, Dominici M, Evangelista M, Falk W, Hennerbichler S, Hess DC, Lanzoni G, Liu B, Marongiu F, McGuckin C, Mohr S, Nolli ML, Ofir R, Ponsaerts P, Romagnoli L, Solomon A, Soncini M, Strom S, Surbek D, Venkatachalam S, Wolbank S, Zeisberger S, Zeitlin A, Zisch A, Borlongan CV. Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev. 2010 Feb;19(2):143-54. doi: 10.1089/scd.2009.0404. Review. PubMed PMID: 19947828.

30. Dominici M, Paolucci P, Conte P, Horwitz EM. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation. 2009 May 15;87(9 Suppl):S36-42. doi: 10.1097/TP.0b013e3181a283ee. PubMed PMID: 19424002.

31. Dominici M, Rasini V, Bussolari R, Chen X, Hofmann TJ, Spano C, Bernabei D, Veronesi E, Bertoni F, Paolucci P, Conte P, Horwitz EM. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood. 2009 Sep 10;114(11):2333-43. doi:10.1182/blood-2008-10-183459. Epub 2009 May 11. PubMed PMID: 19433859; PubMed Central PMCID: PMC2745851.

32. Jethva R, Otsuru S, Dominici M, Horwitz EM. Cell therapy for disorders of bone. Cytotherapy. 2009;11(1):3-17. doi: 10.1080/14653240902753477. Review. PubMed PMID: 19191055.

33. Otsuru S, Hofmann TJ, Olson TS, Dominici M, Horwitz EM. Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device. Cytotherapy. 2013 Feb;15(2):146-53. doi: 10.1016/j.jcyt.2012.10.012. Epub 2012 Dec 6. PubMed PMID: 23321326.

26

ONCOLOGIA

VALENTINA GUARNERI

HIRSCH SCOPUS: 21


1. Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3. PubMed PMID: 24590635.

2. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. PubMed PMID: 24401929; PubMed Central PMCID: PMC3933248.

3. Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7. PubMed PMID: 24013581.

4. Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6. Review. PubMed PMID: 23842749.

5. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013 Jan;24(1):101-8. doi: 10.1093/annonc/mds248. Epub 2012 Sep 20. PubMed PMID: 23002281.

6. Cortesi L, Marcheselli L, Guarneri V, Cirilli C, Braghiroli B, Toss A, Sant M, Ficarra G, Conte PF, Federico M. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years.

27

Int J Cancer. 2013 Jan 15;132(2):E58-65. doi: 10.1002/ijc.27795. Epub 2012 Sep 21. PubMed PMID: 22915138.

7. Conte P, Guarneri V. The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer. Clin BreastCancer. 2012 Jun;12(3):157-66. doi: 10.1016/j.clbc.2012.03.005. Review. PubMed PMID: 22607765.

8. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012 Jun 1;30(16):1989-95. doi: 10.1200/JCO.2011.39.0823. Epub 2012 Apr 9. PubMed PMID: 22493419.


10. Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother. 2012 Feb;13(3):395-406. doi: 10.1517/14656566.2012.651127. Epub 2012 Jan 21. Review. PubMed PMID: 22263900.

11. Guarneri V, Barbieri E, Conte P. Biomarkers predicting clinical benefit: fact or fiction?J Natl Cancer Inst Monogr. 2011;2011(43):63-6. doi: 10.1093/jncimonographs/lgr021. PubMed PMID: 22043043.

12. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, Loschi P, Pignatti M, Di Benedetto F, Ballarin R, Di Gregorio C, Guarneri V, Piccinini L, Horwitz EM, Paolucci P, Conte P, Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res. 2011;1(6):787-805. Epub 2011 May 28. PubMed PMID: 22016827; PubMed Central PMCID: PMC3195936.

13. Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab treatment for advanced breast cancer.

28

Oncologist. 2011;16(12):1684-97. doi: 10.1634/theoncologist.2011-0113. Epub 2011 Oct 5. Review. PubMed PMID: 21976315; PubMed Central PMCID: PMC3248767.

14. Piacentini F, Rossi G, Casali C, Cadioli A, Barbieri E, Guarneri V. Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. Lung Cancer. 2011 Oct;74(1):145-8. doi: 10.1016/j.lungcan.2011.06.008. Epub 2011 Jul 20. Review. PubMed PMID: 21767893.





19. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2. PubMed PMID: 20361252.


21. Guarneri V. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.

29

Expert Rev Anticancer Ther. 2009 Nov;9(11):1549-57. doi: 10.1586/era.09.124. Review. PubMed PMID: 19895239.

22. Frassoldati A, Guarneri V, Conte P. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1456-8. Epub 2009 Aug 5. PubMed PMID: 19617703.

23. Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009 Jul;14(7):645-56. doi: 10.1634/theoncologist.2009-0078. Epub 2009 Jul 16. Review. PubMed PMID: 19608638.


30

ONCOLOGIA

GABRIELE LUPPI

HIRSCH SCOPUS: 21


1. Ponti G, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. J Clin Pathol. 2013 May;66(5):441-5. doi: 10.1136/jclinpath-2012-201345. Epub 2013 Mar 5. PubMed PMID: 23463675.

2. Di Benedetto F, Berretta M, D'Amico G, Montalti R, De Ruvo N, Cautero N, Guerrini GP, Ballarin R, Spaggiari M, Tarantino G, Di Sandro S, Pecchi A, Luppi G, Gerunda GE. Liver resection for colorectal metastases in older adults: a paired matched analysis. J Am Geriatr Soc. 2011 Dec;59(12):2282-90. doi: 10.1111/j.1532-5415.2011.03734.x. PubMed PMID: 22188075.

3. Bertolini F, Rossi G, Fiocchi F, Giacometti M, Fontana A, Gibertini MC, Roncucci L, Luppi G, Torricelli P, Rossi A, Conte PF. Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor. Tumori. 2011 Sep-Oct;97(5):27e-30e. doi: 10.1700/989.10734. PubMed PMID: 22158506.

4. Fiocchi F, Iotti V, Ligabue G, Malavasi N, Luppi G, Bagni B, Torricelli P. Role of carcinoembryonic antigen, magnetic resonance imaging, and positron emission tomography-computed tomography in the evaluation of patients with suspected local recurrence of colorectal cancer. Clin Imaging. 2011 Jul-Aug;35(4):266-73. doi: 10.1016/j.clinimag.2010.07.010. PubMed PMID: 21724118.

5. Ponti G, Luppi G, Losi L, Cesinaro AM, Sartori G, Maiorana A, Pellacani G, Longo C, Boni E, Pepe P, Giannetti A, Seidenari S, Landi MT. p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome. Int J Dermatol. 2012 Apr;51(4):488-92. doi: 10.1111/j.1365-4632.2010.04496.x. Epub 2011 Jun 15. PubMed PMID: 21671908.

31

6. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011 Jul 10;29(20):2773-80. doi: 10.1200/JCO.2010.34.4911. Epub 2011 May 23. PubMed PMID: 21606427.

7. Cascinu S, Galizia E, Labianca R, Ferraù F, Pucci F, Silva RR, Luppi G, Beretta GD, Berardi R, Scartozzi M. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011 Jul;68(1):37-43. doi: 10.1007/s00280-010-1424-8. Epub 2010 Sep 7. PubMed PMID: 20821330.

8. Ponti G, Luppi G, Giacobbi F, Corradini G, Temperani P, Losi L, Ferrara L, Pagano M, Seidenari S, Tagliafico E, Torelli G, Conte P. Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. Cancer Genet Cytogenet. 2010 Jul 1;200(1):1-7. doi: 10.1016/j.cancergencyto.2009.10.006. PubMed PMID: 20513527.

9. Ponti G, Luppi G, Losi L, Giannetti A, Seidenari S. Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers. J Hematol Oncol. 2010 Jan 11;3:2. doi: 10.1186/1756-8722-3-2. PubMed PMID: 20064244; PubMed Central PMCID: PMC2820021.

10. Ponti G, Luppi G, Martorana D, Rossi G, Losi L, Bertolini F, Sartori G, Pellacani G, Seidenari S, Boni E, Neri TM, Silini E, Tamburini E, Maiorana A, Conte PF. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep. 2010 Feb;23(2):437-44. PubMed PMID: 20043105.

11. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23. PubMed PMID: 19933912.

12. Malavasi N, Ponti G, Depenni R, Bertolini F, Zironi S, Luppi G, Conte PF. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. J Hematol Oncol. 2009 Aug 6;2:35. doi: 10.1186/1756-8722-2-35. PubMed PMID: 19660136; PubMed Central PMCID: PMC2731036.

32

13. Berardi R, Mantello G, Scartozzi M, Del Prete S, Luppi G, Martinelli R, Fumagalli M, Grillo-Ruggieri F, Bearzi I, Mandolesi A, Marmorale C, Cascinu S. Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1437-43. doi: 10.1016/j.ijrobp.2009.01.016. Epub 2009 Apr 20. PubMed PMID: 19386440.

14. Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, Malavasi N, Scolaro T, Depenni R, Jovic G, Sonaglio C, Rossi A, Luppi G, Conte PF. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):466-72. doi: 10.1016/j.ijrobp.2008.04.065. Epub 2008 Nov 10. PubMed PMID: 19004567.

33

ONCOLOGIA

MICHELA MAUR

HIRSCH SCOPUS: 9


1. Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res. 2013 Oct 25;32(1):82. doi: 10.1186/1756-9966-32-82. PubMed PMID: 24423086.

2. Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012 Feb 20;30(6):e76-8. doi: 10.1200/JCO.2011.38.7886. Epub 2011 Dec 27. PubMed PMID: 22203769.

3. Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20. PubMed PMID: 20855840.

4. Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL, Luminari S, Maur M, Frassoldati A, Palazzi G, Otsuru S, Bambi F, Paolucci P, Pierfranco C, Horwitz E, Dominici M. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy. 2010 Jul;12(4):466-77. doi: 10.3109/14653241003649510. PubMed PMID: 20353309.

34

ONCOLOGIA

FEDERICO PIACENTINI

HIRSCH SCOPUS: 9


1. Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P.Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3. PubMed PMID: 24590635.

2. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013 Jan;24(1):101-8. doi: 10.1093/annonc/mds248. Epub 2012 Sep 20. PubMed PMID: 23002281.

3. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P.Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012 Jun 1;30(16):1989-95. doi: 10.1200/JCO.2011.39.0823. Epub 2012 Apr 9. PubMed PMID: 22493419.


5. Piacentini F, Rossi G, Casali C, Cadioli A, Barbieri E, Guarneri V. Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. Lung Cancer. 2011 Oct;74(1):145-8. doi: 10.1016/j.lungcan.2011.06.008. Epub 2011 Jul 20. Review. PubMed PMID: 21767893.

35







12. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte P. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist. 2008 Aug;13(8):838-44. doi: 10.1634/theoncologist.2008-0048. Epub 2008 Jul 23. PubMed PMID: 18650259.

36

ONCOLOGIA

ROBERTO SABBATINI

HIRSCH SCOPUS: 10


1. Procopio G, Derosa L, Gernone A, Morelli F, Sava T, Zustovich F, De Giorgi U, Ferrari V, Sabbatini R, Gasparro D, Felici A, Burattini L, Calvani N, Lo Re G, Banna G, Brizzi MP, Rizzo M, Ciuffreda L, Iacovelli R, Ferraù F, Taibi E, Bracarda S, Porta C, Galligioni E, Contu A. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol. 2014 Mar 18. [Epub ahead of print] PubMed PMID: 24641206.

2. Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzì V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, Bracarda S. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLoS One. 2013 Dec 30;8(12):e83026. doi: 10.1371/journal.pone.0083026. eCollection 2013. PubMed PMID: 24386138; PubMed Central PMCID: PMC3875424.

3. Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 2013 Nov;33(11):4999-5004. PubMed PMID: 24222142.

4. Santoni M, De Tursi M, Felici A, Lo Re G, Ricotta R, Ruggeri EM, Sabbatini R, Santini D, Vaccaro V, Milella M. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther. 2013 Jun;13(6):697-709. doi: 10.1586/era.13.52. Review. PubMed PMID: 23773104.

5. Sabbatini R, Ortega C, Procopio G, Masini C, Galligioni E, Porta C. Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol. 2013 Jun;9(6):831-43. doi: 10.2217/fon.13.58. Review. PubMed PMID: 23718304.

6. Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.

37

Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18. PubMed PMID: 23518211.

7. Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther. 2012 Dec;12(12):1571-7. doi: 10.1586/era.12.81. Epub 2012 Nov 26. Review. PubMed PMID: 23181412.

8. Procopio G, Sabbatini R, Porta C, Verzoni E, Galligioni E, Ortega C.Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2012 Aug;12(8):1089-96. doi: 10.1586/era.12.76. Review. PubMed PMID: 23030227.

9. Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 2012 Sep;110(5):692-8. doi: 10.1111/j.1464-410X.2012.10946.x. Epub 2012 Feb 24. PubMed PMID: 22364110.

10. Ravasio R, Ortega C, Sabbatini R, Porta C. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig. 2011;31(7):507-17. doi: 10.2165/11590230-000000000-00000. PubMed PMID: 21627339.

11. Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E,Rizzo M, Paglino C, Guadalupi V, Bajetta E. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicenter retrospective analysis of 189 patient cases. BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23. PubMed PMID: 21599821.

12. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol. 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402. PubMed PMID: 20857484.

13. Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets. 2010 Feb;10(1):46-54. Review. PubMed PMID: 20088792.

38

14. Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. PubMed PMID: 19779715.

39

doe.unimore.itdoe.unimore.it/accreditamento10s2015/12.3. pubblicazioni... · web viewdoe.unimore.it

Documents